Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Cohen, Paris
Annick Cohen, Paris FR
| Patent application number | Description | Published |
|---|---|---|
| 20080305483 | BIALLELIC MARKERS DERIVED FROM GENOMIC REGIONS CARRYING GENES INVOLVED IN ARACHIDONIC ACID METABOLISM - The invention provides polynucleotides including biallelic markers derived from genes involved in arachidonic acid metabolism and from genomic regions flanking those genes. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype. | 12-11-2008 |
Caroline Cohen, Paris FR
| Patent application number | Description | Published |
|---|---|---|
| 20090247583 | PHARMACEUTICAL COMPOSITION COMPRISING, IN COMBINATION, SAREDUTANT AND PAROXETINE - A subject-matter of the present invention is pharmaceutical compositions comprising, in combination, at least one active ingredient chosen from (S)-(−)-N-[4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from trans-(−)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine and pharmaceutically acceptable salts thereof. | 10-01-2009 |
| 20090247585 | PHARMACEUTICAL COMPOSITION COMPRISING, IN COMBINATION, SAREDUTANT AND ESCITALOPRAM - A subject-matter of the present invention is pharmaceutical compositions comprising, in combination, at least one active ingredient chosen from (S)-(−)-N-[4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from (S)-(+)-1-[4-(3-(dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile and pharmaceutically acceptable salts thereof. | 10-01-2009 |
Celine Cohen, Paris FR
| Patent application number | Description | Published |
|---|---|---|
| 20110236954 | CELLULASE PRODUCTION METHOD BASED ON THE REGULATION OF THE DISSOLVED OXYGEN PRESSURE OSCILLATION IN THE CULTURE MEDIUM - The present invention relates to a method of producing cellulolytic and/or hemicellulolytic enzymes by a cellulolytic microorganism in a stirred and aerated bioreactor, comprising a growth stage in the presence of a carbon source and a production stage in the presence of a carbon-containing inductive substrate, wherein the supply of carbon-containing inductive substrate during the production stage is regulated by an oscillation of the dissolved oxygen partial pressure in the medium. | 09-29-2011 |
Ivan Cohen, Paris FR
| Patent application number | Description | Published |
|---|---|---|
| 20100028371 | Preparation of recombinant rotavirus proteins in milk of transgenic non-human mammals - The present invention relates to a non-human transgenic mammal whose genome comprises: i) a first transgene comprising a mammary gland specific transcriptional control region operably linked to cDNA encoding a rotavirus protein selected from VP2, VP4, VP6 and VP7 and wherein said cDNA comprises a secretion signal sequence; ii) at least a second transgene comprising a mammary gland specific transcriptional control region operably linked to cDNA encoding another said rotavirus protein and wherein said cDNA comprises a secretion signal sequence; and wherein said rotavirus proteins are secreted separately and auto-assembled in milk in rotavirus like particles (VLP) or aggregates of said rotavirus proteins. | 02-04-2010 |
Jean Cohen, Paris FR
| Patent application number | Description | Published |
|---|---|---|
| 20100028371 | Preparation of recombinant rotavirus proteins in milk of transgenic non-human mammals - The present invention relates to a non-human transgenic mammal whose genome comprises: i) a first transgene comprising a mammary gland specific transcriptional control region operably linked to cDNA encoding a rotavirus protein selected from VP2, VP4, VP6 and VP7 and wherein said cDNA comprises a secretion signal sequence; ii) at least a second transgene comprising a mammary gland specific transcriptional control region operably linked to cDNA encoding another said rotavirus protein and wherein said cDNA comprises a secretion signal sequence; and wherein said rotavirus proteins are secreted separately and auto-assembled in milk in rotavirus like particles (VLP) or aggregates of said rotavirus proteins. | 02-04-2010 |
Jose Cohen, Paris FR
| Patent application number | Description | Published |
|---|---|---|
| 20100215629 | TREATMENT OF TUMORS USING T LYMPHOCYTE PREPARATIONS - The invention relates to the treatment of a tumor in a patient, by injecting T lymphocytes depleted of regulatory T lymphocytes, and expressing a molecule allowing their specific destruction, the patient receiving beforehand a non-myeloablative or myeloablative lymphopenic treatment. | 08-26-2010 |
| 20100233144 | METHOD FOR OPTIMIZING BLOOD CELL TRANSPLANTS - The invention relates to the use of allogenic T lymphocytes for the preparation of a composition intended to be injected into a recipient patient as a conditioning for a transplantation of haematopoietic stem cells, said allogenic T lymphocytes expressing a molecule allowing their specific destruction. | 09-16-2010 |
Marcel Georges Cohen, Paris FR
| Patent application number | Description | Published |
|---|---|---|
| 20090232757 | Use of gamma-amino butyric acid as a depigmenting agent - Use of gamma aminobutyric acid, one of its salts or one of its lower alkyl ester or a polyol ester as depigmenting or melano modulating agent. | 09-17-2009 |
Michel Cohen, Paris FR
| Patent application number | Description | Published |
|---|---|---|
| 20090023385 | METHOD FOR SYNCHRONZING USER SIGNAL TRANSMISSIONS WITHIN A HYBRID COMMUNICATION NETWORK - A method is devoted to synchronizing the transmission of user signals within a single-frequency hybrid network comprising at least one transmission satellite (SAT) and regenerative emitters (E | 01-22-2009 |
Serge Cohen, Paris FR
| Patent application number | Description | Published |
|---|---|---|
| 20100028371 | Preparation of recombinant rotavirus proteins in milk of transgenic non-human mammals - The present invention relates to a non-human transgenic mammal whose genome comprises: i) a first transgene comprising a mammary gland specific transcriptional control region operably linked to cDNA encoding a rotavirus protein selected from VP2, VP4, VP6 and VP7 and wherein said cDNA comprises a secretion signal sequence; ii) at least a second transgene comprising a mammary gland specific transcriptional control region operably linked to cDNA encoding another said rotavirus protein and wherein said cDNA comprises a secretion signal sequence; and wherein said rotavirus proteins are secreted separately and auto-assembled in milk in rotavirus like particles (VLP) or aggregates of said rotavirus proteins. | 02-04-2010 |